Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Aviragen Therapeutics
Alpharetta, Georgia, United Statesaviragentherapeutics.com ↗
- Ownership
- Public · VXRT
- Employees
- ~200
- Development stage
- Other
01
Overview
Aviragen had several Phase 2 clinical programs including vapendavir (failed Phase 2b SPIRITUS study in asthma patients with rhinovirus infection), BTA585/enzaplatovir (failed to reduce viral load in Phase 2a RSV challenge study), and teslexivir/BTA074 (completed patient enrollment in Phase 2 trial for condyloma treatment with results expected in Q2 2018)[6][9]
- Therapeutic areas
- PulmonologyInfectious Diseases
- Modalities
- Small moleculesdirect-acting antivirals
- Industry
- Biotech
02
Partnerships
Georgia State University Research Foundation
Beyond the preview
Go deeper on Aviragen Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aviragen Therapeutics.